Skip to main content
TipRanks
Go Ultimate75% OFF

Edwards Lifesciences (0REN) Share Price & Analysis

1 Followers

0REN Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 51.70B
Enterprise Value
CHF 46.02B
Total Cash (Recent Filing)
CHF 4.64B
Total Debt (Recent Filing)
CHF 704.50M
Price to Earnings (P/E)
60.5
Beta
N/A
Next Earnings
Jan 27, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet Strength

Very low leverage and steadily rising equity provide Edwards with financial flexibility to fund research, regulatory programs, and commercial expansion. This balance-sheet strength can help the company absorb operating volatility while preserving capacity to invest in structural-heart opportunities over the next several quarters.

Revenue And EPS Growth Outlook

Raised sales and adjusted EPS guidance indicates that current demand, product adoption, and execution are supporting growth beyond a single product cycle. Management also reaffirmed approximately 10% long-term annual sales growth with EPS leverage, strengthening the outlook for continued earnings expansion.

Clinical And Regulatory Expansion

Multiple approvals and clinically meaningful evidence can expand eligible patient populations, support physician adoption, and reinforce Edwards' position in structural heart. These developments create a broader product and indication base, making future growth less dependent on one procedure or mature market.

Bears Say

Operating Margin Compression

The decline in operating profitability suggests that higher costs, investment intensity, or product mix are absorbing part of the benefit from revenue growth. Unless margins recover, earnings may compound more slowly than sales and the company will have less operating leverage during periods of demand or currency pressure.

Volatile Free Cash Flow

Edwards generates substantial cash, but uneven free-cash-flow momentum and weak conversion in some periods reduce confidence in the consistency of internally funded growth. Continued volatility could constrain the timing of investments, shareholder returns, or other capital-allocation decisions even with a strong balance sheet.

Increasing Competitive Pressure

A plateau in TAVR share gains means future growth must rely more heavily on procedure expansion and new indications rather than continued competitive capture. As additional competitors enter, potential share loss could pressure pricing, volume growth, and the durability of Edwards' leadership in its core franchise.

Edwards Lifesciences News

0REN FAQ

What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is CHF51.70B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s next earnings report is estimated for Jan 27, 2027 (not yet confirmed), which is in 72 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Nov 04, 2026. The company reported CHF0.671 earnings per share for the quarter, beating the consensus estimate of CHF0.624 by CHF0.047.
Is Edwards Lifesciences overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.56.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 575,000,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of CHF0.671 in its last earnings report, beating expectations of CHF0.624. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Hedge funds hold Edwards Lifesciences shares: the largest hedge-fund position in Edwards Lifesciences is 907,330,361 shares, and hedge funds decreased their holdings by 1.3M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology